There is the inbetween option of taking the drug through one or more phase 3s and then licensing without going all the way to market. In that case the responsibility for distribution would fall on who they licensed to and the deal would be more sizeable having progressed the compound further. I think that would be what Neuren are thinking as taking on the distribution aspect is a big step that current management aren't likely to have any experience.
There is the inbetween option of taking the drug through one or...
-
- There are more pages in this discussion • 133 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.39 |
Change
-0.470(2.37%) |
Mkt cap ! $2.478B | |||
| Open | High | Low | Value | Volume |
| $19.70 | $19.77 | $19.28 | $10.38M | 534.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 2680 | $19.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.41 | 362 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |